Vimian Buys Its Way Into Soft Tissue — and Retires an Old Excuse
Vimian Buys Its Way Into Soft Tissue — and Retires an Old Excuse
Vimian's Q3 was, on the numbers, a clean quarter: revenue up 15% to €120 million, organic growth of 11%, adjusted EBITDA up 14% to €29.2 million at a 24.3% margin, cash conversion of 71%, and net debt down to €262.4 million for leverage of 2.0x. Five acquisitions closed year to date. Nothing broken. But the interesting work in this transcript isn't in the income statement — it's in what the company started saying, what it stopped saying, and what it kept saying on autopilot.
The genuinely new thing: soft tissue surgery
Two days before the call, Vimian signed Norfolk Medical Products, a U.S. niche player in tissue surgery — specifically implants and consumables, including a well-known urinary bypass implant for cats and dogs. This is the first thematically new thing the company has said in four quarters. Scanning Vimian's own keyword history back to late 2024, the recurring cast is vet service memberships, dental margins, companion animal investment, and the U.S. orthopedics turnaround. Soft tissue surgery has never appeared. It also appears nowhere in the market-wide keyword lists, which this quarter are a wall of tariff levels, fuel costs and AI data center anxiety. Animal-health niches have no seat at the market's table — this is a company-unique signal, not a wave Vimian is riding.
The strategic logic is unusually clean: Norfolk's customer base is largely the same specialty clinics Vimian already sells orthopedics into, and the target has almost no sales force. “Many orthopedic clinics also do soft tissue surgery... So we see good opportunities to grow the business by leveraging our Medtech sales force across the globe.” — Alireza Tajbakhsh, Group CEO · 2026-10-22 That is a distribution acquisition, not a technology bet — the cheapest kind of M&A to underwrite.
The caveat is margin. Norfolk carries a lower margin profile than the group, and at roughly $6.9 million of annual revenue it is small. Vimian paid its customary price, and the CFO's phrasing that “our historical multiple has been around the 9x for EBITDA” — Alireza Tajbakhsh, Group CEO · 2026-10-22 drew an immediate follow-up demanding a range. That is the tell: the 9x answer is now such a fixed script that analysts ask the question knowing the answer, exactly as they did in February, when the same CFO said “we have a historical average of approximately 9x EBITDA, and we are around that average.” — Carl Johan Boudrie, CFO · 2026-02-12 Capital allocation is consistent. It is also no longer news.
The old thing, repeated for a third quarter
Here is the tension worth flagging. Vimian's U.S. orthopedics business has been the drag for over a year, and every call since February has been anchored to the same phrase. In February: “we see the U.S. surgery market condition remaining relatively unchanged. There are signs of stabilization, but I don't think it's returned to healthy growth yet.” — Alireza Tajbakhsh, Group CEO · 2026-02-12 In July: “we expect a continued slow single digit growth in the second half of the year as well. We still see unchanged market condition.” — Alireza Tajbakhsh, Group CEO · 2026-07-17 And on Thursday, the phrase minted itself into a keyword ranked in the company's top ten: “US Orthopaedics was low single digit in unchanged market condition, and we do not expect the market condition to change in the fourth quarter.” — Alireza Tajbakhsh, Group CEO · 2026-10-22 Three calls, three quarters, one sentence.
We believe the current growth rate is what we expect in kind of short term future. We are happy to see that the changes we implemented earlier this year has shown positive effect, and we are confident that the existing new management team will continue to drive operational improvements.
Read that against the prior quarter's language about "operational improvements" and a new management team, and the honest conclusion is that the U.S. ortho recovery is real but shallow — low single digit, market-dependent, with acceleration explicitly deferred to 2027 and explicitly dependent on the market rather than on Vimian. Management is not overselling it, which is to their credit. But the "turnaround" framing that the segment keyword history implies is not supported by the guidance.
What quietly got better — and what got quiet
Two smaller stories sit underneath. First, the working-capital complaint from July has been resolved. Analysts hammered the company on high receivables, and the CFO promised then that it “will normalize during the third quarter.” — Carl-Johan Zetterberg Boudrie, CFO and interim Head of Specialty Pharma · 2026-07-17 It did: net working capital fell to 25% of revenue from 26%, and operating cash flow reached €22.6 million. Notably, cash conversion — a top-five keyword for the company in Q4 2025 — has fallen out of the curated list entirely, and appropriately so: it stopped being a problem.
Second, national sales campaign mechanics in Specialty Pharma are finally washing out. Organic growth of 7% becomes 11% adjusting for last year's U.S. specialized nutrition program, and management was emphatic that the comparison distortion is finished. The segment's underlying story — allergy, dermatology, specialty pharma all double digit — is intact, and the allergy test platform refresh (PAX, 25 additional allergens) is a real product event rather than a narrative one.
The segment that deserves scrutiny is Diagnostics: €0.5 million of EBITDA, a 7.2% margin, held down by IVET integration costs and deliberate companion-animal investment. The CFO pushed the recovery to 2027: “we foresee in 2027 and onwards that margins will pick up in the Diagnostics segments as our companion animal business starts to scale.” — Carl-Johan Zetterberg Boudrie, CFO · 2026-10-22 That is the second consecutive single-digit-margin quarter. Watch it.
Veterinary Services, meanwhile, carried the quarter — 10% organic, 12.4 thousand member clinics, EBITDA margin of 30.5% helped by partner agreements mix, with the CFO guiding Q4 back to the 28.5–29% run rate. The analyst push on member penetration met a polite wall: “there is still white space and growth opportunities in all 14 of the markets we are in” — Alireza Tajbakhsh, Group CEO · 2026-10-22 — but no penetration ratio. Japan and Portugal went live at quarter-end, contributing essentially nothing yet. The new members flywheel is the most valuable asset here and the least quantified.
Why it matters from here
Leverage at 2.0x against a stated ceiling of 3.0x, with the CFO claiming “significant headroom for us to drive further M&A” — Carl-Johan Zetterberg Boudrie, CFO · 2026-10-22 and a pipeline spanning bolt-ons and larger platforms, sets up a busy 2027. The nearer catalyst is November 24, Vimian's first Capital Markets Day in Stockholm, where management promises the roadmap to 2030 targets. That is where a company that has been judged quarter-by-quarter on U.S. ortho market conditions will attempt to reset the frame toward the compounding parts: veterinary services memberships, companion diagnostics, and now a surgical platform.
For now: a good quarter, a sensible acquisition, and a management team that told the truth about a soft end market for the third time running. The market's keyword tape is shouting about tariffs and AI infrastructure; Vimian is quietly assembling an animal-health compounder. Those two facts can both be true, and that is precisely why this report is more interesting than its headline growth rate.